Acurx Pharmaceuticals, Inc. research brief

CIK 1736243 Copy CIK

Generated Nov. 7, 2026, 8:23 p.m. from up to 100 stored Form D disclosures. A CIK identifies a filer, not a single offering.

Current stored business address: STATEN ISLAND NY. Reported legal jurisdiction: DELAWARE. These do not establish investor residence or where funds were deployed.

• April 29, 2026 · D · 0001736243-26-000001 · Source evidence

  Reported offering amount: 4587473 USD. Reported amount sold: 4587473 USD.

• June 27, 2025 · D · 0001104659-25-063623 · Source evidence

  Reported offering amount: 3978664 USD. Reported amount sold: 3978664 USD.

• May 20, 2025 · D · 0001736243-25-000003 · Source evidence

  Reported offering amount: 12000000 USD. Reported amount sold: 0 USD.

• March 21, 2025 · D · 0001736243-25-000002 · Source evidence

  Reported offering amount: 3376350 USD. Reported amount sold: 3376350 USD.

• Jan. 17, 2025 · D · 0001736243-25-000001 · Source evidence

  Reported offering amount: 2404259 USD. Reported amount sold: 2404259 USD.

Reviewed offering links

• No independently reviewed offering relationship is recorded. Adjacent filings are not assumed to belong to one offering.

Citation: Form D Explorer, “Acurx Pharmaceuticals, Inc. research brief,” CIK 1736243, retrieved Nov. 7, 2026, 8:23 p.m.. Cite the specific accessions used. No amounts have been summed.